Literature DB >> 18547495

Comparison between continuous or intermittent schedules of sublingual immunotherapy for house dust mites: effects on compliance, patients satisfaction, quality of life and safety.

G Cadario, G Ciprandi, G Di Cara, R Fadel, C Incorvaia, F Marcucci, F Marengo, P Puccinelli, L Sensi, L Strazzeri, F Frati.   

Abstract

Sublingual immunotherapy (SLIT) is indicated in the treatment of allergic rhinitis and asthma. However, an issue scantly investigated is the patients satisfaction and the consequent compliance. This study is aimed at evaluating the possible differences of SLIT administered continuously or intermittently on several parameters: clinical efficacy, Quality of Life (QoL), satisfaction, compliance and safety. Forty allergic patients were treated for 12 months. The treatment was carried out by sublingual administration of an allergen extract of a 50% mixture of Dermatophagoides pteronyssinus and Dermatophagoides farinae at 10 and 300 IR/ml concentrations. Patients were randomly treated continuously or intermittently (i.e. 2 month treatment alternate to 2 month suspension). Both schedules were significantly effective in reducing allergic symptoms and improving QoL. Compliance and satisfaction were good in both groups. Local and systemic reactions were few, self-resolving, and mild in both schedules. Intergroup analysis did not reveal any difference between the two groups regarding these parameters. In conclusion, this preliminary study provides the evidence that also intermittent SLIT is as effective and safe as traditional continuous treatment. In addition, compliance and satisfaction are super-imposable in the two groups.

Entities:  

Mesh:

Year:  2008        PMID: 18547495     DOI: 10.1177/039463200802100229

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  10 in total

1.  International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis.

Authors:  Sarah K Wise; Sandra Y Lin; Elina Toskala; Richard R Orlandi; Cezmi A Akdis; Jeremiah A Alt; Antoine Azar; Fuad M Baroody; Claus Bachert; G Walter Canonica; Thomas Chacko; Cemal Cingi; Giorgio Ciprandi; Jacquelynne Corey; Linda S Cox; Peter Socrates Creticos; Adnan Custovic; Cecelia Damask; Adam DeConde; John M DelGaudio; Charles S Ebert; Jean Anderson Eloy; Carrie E Flanagan; Wytske J Fokkens; Christine Franzese; Jan Gosepath; Ashleigh Halderman; Robert G Hamilton; Hans Jürgen Hoffman; Jens M Hohlfeld; Steven M Houser; Peter H Hwang; Cristoforo Incorvaia; Deborah Jarvis; Ayesha N Khalid; Maritta Kilpeläinen; Todd T Kingdom; Helene Krouse; Desiree Larenas-Linnemann; Adrienne M Laury; Stella E Lee; Joshua M Levy; Amber U Luong; Bradley F Marple; Edward D McCoul; K Christopher McMains; Erik Melén; James W Mims; Gianna Moscato; Joaquim Mullol; Harold S Nelson; Monica Patadia; Ruby Pawankar; Oliver Pfaar; Michael P Platt; William Reisacher; Carmen Rondón; Luke Rudmik; Matthew Ryan; Joaquin Sastre; Rodney J Schlosser; Russell A Settipane; Hemant P Sharma; Aziz Sheikh; Timothy L Smith; Pongsakorn Tantilipikorn; Jody R Tversky; Maria C Veling; De Yun Wang; Marit Westman; Magnus Wickman; Mark Zacharek
Journal:  Int Forum Allergy Rhinol       Date:  2018-02       Impact factor: 3.858

Review 2.  SLIT's Prevention of the Allergic March.

Authors:  Federica Porcaro; Giovanni Corsello; Giovanni Battista Pajno
Journal:  Curr Allergy Asthma Rep       Date:  2018-04-21       Impact factor: 4.806

Review 3.  Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases.

Authors:  Charles B Smarr; Paul J Bryce; Stephen D Miller
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

Review 4.  Sublingual immunotherapy for asthma.

Authors:  Rebecca Normansell; Kayleigh M Kew; Amy-Louise Bridgman
Journal:  Cochrane Database Syst Rev       Date:  2015-08-28

5.  Requirements for acquiring a high-quality house dust mite extract for allergen immunotherapy.

Authors:  Franco Frati; Cristoforo Incorvaia; Marie David; Silvia Scurati; Simona Seta; Guglielmo Padua; Eleonora Cattaneo; Carlo Cavaliere; Alessia Di Rienzo; Ilaria Dell'Albani; Paola Puccinelli
Journal:  Drug Des Devel Ther       Date:  2012-05-18       Impact factor: 4.162

Review 6.  Burden of allergic respiratory disease: a systematic review.

Authors:  A Linneberg; K Dam Petersen; J Hahn-Pedersen; E Hammerby; N Serup-Hansen; N Boxall
Journal:  Clin Mol Allergy       Date:  2016-09-28

7.  Sublingual immunotherapy in children: facts and needs.

Authors:  Gian Luigi Marseglia; Cristoforo Incorvaia; Mario La Rosa; Franco Frati; Francesco Marcucci
Journal:  Ital J Pediatr       Date:  2009-10-23       Impact factor: 2.638

8.  Patient's compliance with allergen immunotherapy.

Authors:  Cristoforo Incorvaia; Marina Mauro; Erminia Ridolo; Paola Puccinelli; Massimiliano Liuzzo; Silvia Scurati; Franco Frati
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

9.  Sublingual immunotherapy for asthma.

Authors:  Rebecca Fortescue; Kayleigh M Kew; Marco Shiu Tsun Leung
Journal:  Cochrane Database Syst Rev       Date:  2020-09-14

10.  Prospective adherence to specific immunotherapy in Europe (PASTE) survey protocol.

Authors:  Melina Makatsori; Gianenrico Senna; Constantinos Pitsios; Ramon Lleonart; Ludger Klimek; Carlos Nunes; Maia Rukhadze; Barbara Rogala; Radoslaw Gawlik; Petr Panzner; Oliver Pfaar; Moises Calderon
Journal:  Clin Transl Allergy       Date:  2015-04-27       Impact factor: 5.871

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.